Display options
Share it on

Ann Transl Med. 2019 Mar;7(5):88. doi: 10.21037/atm.2019.01.10.

Improved long-term survival following pulmonary resections for non-small cell lung cancer: results of a nationwide study from Iceland.

Annals of translational medicine

Hannes Halldorsson, Andri Wilberg Orrason, Gudrun Nina Oskarsdottir, Astridur Petursdottir, Bjorn Mar Fridriksson, Magnus Karl Magnusson, Steinn Jonsson, Tomas Gudbjartsson

Affiliations

  1. Department of Cardiothoracic Surgery, Landspitali University Hospital, Reykjavik, Iceland.
  2. Department of Pulmonology, Skåne University Hospital, Lund, Sweden.
  3. Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  4. Department of Pulmonology, Landspitali University Hospital, Reykjavik, Iceland.

PMID: 31019938 PMCID: PMC6462663 DOI: 10.21037/atm.2019.01.10

Abstract

BACKGROUND: We studied the outcome of pulmonary resection with curative intent for non-small cell lung cancer (NSCLC) in a nationwide study covering a 24-year period, focusing on survival.

METHODS: All patients who underwent pulmonary resection for NSCLC in Iceland in the period 1991-2014 were reviewed for demographics, TNM stage and survival. Median length of follow-up was 45 months. Three 8-year periods were compared, overall survival was estimated, and prognostic factors for survival were identified.

RESULTS: Altogether, 652 surgical resections were performed on 644 individuals (52% females): 492 lobectomies (75%), 77 pneumonectomies (12%), and 83 sublobar resections (13%). Mean age increased from 65 to 68 yrs during the study period (P=0.002). The number of cases operated at stage IA increased substantially between the first and last periods (29%

CONCLUSIONS: Survival of patients who have undergone pulmonary resection for NSCLC has improved significantly in Iceland. This may be explained by the increased number of patients diagnosed at lower stages and improved preoperative staging, with fewer understaged patients.

Keywords: Non-small cell lung cancer (NSCLC); long-term survival; outcome; prognosis; pulmonary resection

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

  1. J Thorac Cardiovasc Surg. 1999 May;117(5):969-79 - PubMed
  2. Chest. 2000 Feb;117(2):374-9 - PubMed
  3. Eur J Cardiothorac Surg. 2007 Jul;32(1):29-34 - PubMed
  4. J Thorac Oncol. 2010 Jan;5(1):23-8 - PubMed
  5. Acta Oncol. 2010 Jun;49(5):725-36 - PubMed
  6. Ann Thorac Surg. 2010 Sep;90(3):875-81; discussion 881-3 - PubMed
  7. Eur J Cardiothorac Surg. 2013 Jan;43(1):e17-23 - PubMed
  8. Interact Cardiovasc Thorac Surg. 2013 Mar;16(3):270-4 - PubMed
  9. J Korean Med Sci. 2012 Dec;27(12):1486-90 - PubMed
  10. J Thorac Oncol. 2013 May;8(5):554-61 - PubMed
  11. Chest. 2013 May;143(5 Suppl):e278S-e313S - PubMed
  12. Cancer J. 2013 May-Jun;19(3):217-21 - PubMed
  13. Asia Pac J Clin Oncol. 2014 Mar;10(1):75-9 - PubMed
  14. Lancet Oncol. 2014 Jan;15(1):23-34 - PubMed
  15. Ann Oncol. 2014 Aug;25(8):1462-74 - PubMed
  16. Acta Chir Belg. 2014 Jan-Feb;114(1):25-30 - PubMed
  17. Lung Cancer. 2014 Aug;85(2):264-9 - PubMed
  18. Cochrane Database Syst Rev. 2015 Mar 02;(3):CD011430 - PubMed
  19. J Surg Res. 2016 Jan;200(1):171-6 - PubMed
  20. Eur Respir J. 2015 Oct;46(4):1131-9 - PubMed
  21. Eur Respir J. 2016 Jan;47(1):275-87 - PubMed
  22. Eur Respir J. 2016 Aug;48(2):495-503 - PubMed
  23. Eur J Cardiothorac Surg. 2017 Feb 1;51(2):203-210 - PubMed
  24. Acta Oncol. 2017 Jul;56(7):936-942 - PubMed
  25. Interact Cardiovasc Thorac Surg. 2017 May 1;24(5):733-739 - PubMed
  26. ERJ Open Res. 2017 Apr 27;3(2): - PubMed

Publication Types